Literature DB >> 753455

Bone scanning and plasma phosphatases in carcinoma of the prostate.

E P O'Donoghue, A R Constable, T Sherwood, J J Stevenson, G D Chisholm.   

Abstract

Bone scanning with 99mTc-Sn-HEDP, radiographic skeletal survey and determination of plasma acid and alkaline phosphatase values were carried out in a consecutive series of 90 untreated patients with carcinoma of the prostate. 99mTc-Sn-HEDP provided satisfactory bone imaging and was convenient in use. The addition of bone scanning to radiographic survey increases the detection rate of skeletal metatases by 16%. Radiography increases the accuracy of bone scanning by identifying false positive scans due to benign disease and false negative scans when there are diffuse symmetrical bony metastases. The plasma phosphatases alone are less accurate staging tests. The acid phosphatase data support the validity of scan positive--X-ray negative findings. Bone scan abnormalities due to secondary deposits usually precede elevation of plasma alkaline phosphatase.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 753455     DOI: 10.1111/j.1464-410x.1978.tb02797.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  5 in total

1.  [Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Authors:  T Klatte; D Klatte; M Böhm; E P Allhoff
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.

Authors:  O Reikerås; J Due; J A Sundsfjord
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

3.  The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.

Authors:  M Rudoni; G Antonini; M Favro; A Baroli; M Brambilla; G Cardani; L Ciardi; G M Sacchetti; E Inglese
Journal:  Eur J Nucl Med       Date:  1995-03

4.  Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.

Authors:  Vidija Soerdjbalie-Maikoe; Rob C M Pelger; Guus A B Lycklama à Nijeholt; Jan-Willem Arndt; Aeilko H Zwinderman; Herman Bril; Socrates E Papapoulos; Neveen A T Hamdy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236

5.  99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.

Authors:  Maurits Wondergem; Friso M van der Zant; Remco J J Knol; Anne Marij G Burgers; Siebe D Bos; Igle J de Jong; Jan Pruim
Journal:  World J Urol       Date:  2017-10-17       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.